A Study of LY2409021 in Healthy Participants

Lilly

Status and phase: Completed; Phase 1

Conditions: Healthy Participants

Treatments: Drug: LY2409021

Study type: Interventional

Funder types: Industry

Identifiers

NCT02217618

14580

I1R-MC-GLDL (Other Identifier)

Details and patient eligibility

About

The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occur within 30 days prior to the start of the study.

Enrollment: 16 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males or females as determined by medical history
• Satisfactory clinical laboratory and physical examination tests
• Have a body mass index (BMI) of 18 to 32.0 kilograms per meter squared (kg/m^2)

Exclusion criteria

• Abnormal electrocardiograms (ECGs)

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

LY2409021

Experimental group

Description:

Single oral dose of 20 milligrams (mg) LY2409021.

Treatment:

Drug: LY2409021